Legal Representation
Attorney
Jeffrey H. Handelsman
USPTO Deadlines
Next Deadline
418 days remaining
Section 71 Renewal Due (Principal Register 66a) (Based on registration date 20170214)
Due Date
February 14, 2027
Grace Period Ends
August 14, 2027
Application History
50 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 24, 2025 | RNWL | P | INTERNATIONAL REGISTRATION RENEWED | Loading... |
| Apr 18, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Apr 1, 2024 | INNP | P | PARTIAL INVALIDATION PROCESSED BY THE IB | Loading... |
| Feb 26, 2024 | INPS | P | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | Loading... |
| Feb 26, 2024 | INPC | P | INVALIDATION PROCESSED | Loading... |
| Feb 10, 2024 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | Loading... |
| Jun 10, 2023 | NA71 | E | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | Loading... |
| Jun 10, 2023 | 71.P | O | REGISTERED - PARTIAL SEC 71 ACCEPTED | Loading... |
| May 29, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Nov 15, 2022 | ES71 | I | TEAS SECTION 71 RECEIVED | Loading... |
| Feb 14, 2022 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
| Mar 7, 2018 | INNA | R | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | Loading... |
| Feb 23, 2018 | INPR | P | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | Loading... |
| Oct 28, 2017 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Sep 15, 2017 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Sep 15, 2017 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Aug 4, 2017 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Jun 23, 2017 | COC. | O | CORRECTION UNDER SECTION 7 - PROCESSED | Loading... |
| Jun 6, 2017 | PLGL | A | ASSIGNED TO PARALEGAL | Loading... |
| May 14, 2017 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Mar 9, 2017 | ES7R | I | TEAS SECTION 7 REQUEST RECEIVED | Loading... |
| Feb 14, 2017 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Feb 1, 2017 | CHPN | I | POST PUBLICATION AMENDMENT – NOT ENTERED | Loading... |
| Jan 31, 2017 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Dec 28, 2016 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Dec 28, 2016 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Dec 16, 2016 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Dec 16, 2016 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Nov 29, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 29, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 9, 2016 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Nov 9, 2016 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Nov 9, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 27, 2016 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Oct 13, 2016 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 24, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 23, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 23, 2016 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Sep 19, 2016 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | Loading... |
| Sep 15, 2016 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Mar 10, 2016 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 10, 2016 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 10, 2016 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Feb 16, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 15, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 15, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 15, 2016 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 15, 2016 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Sep 4, 2015 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 14, 2015 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
Detailed Classifications
Class 042
[ Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ] * Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; ] research and development in the field of biotechnology; pharmaceutical research and development; [ conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; ] technical project studies in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; research and development of new products for others [ ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals * ]
Additional Information
Other
In the statement, "the entire class 042" should be deleted, and Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals should be inserted.
Classification
International Classes
042